Advertisement

Topics

CAR T-cell therapy shows promise in early-stage lymphoma trial

05:54 EDT 21 Jun 2017 | SmartBrief

Patients with relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma had a 59% complete response rate and an 86% ob -More

Original Article: CAR T-cell therapy shows promise in early-stage lymphoma trial

NEXT ARTICLE

More From BioPortfolio on "CAR T-cell therapy shows promise in early-stage lymphoma trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...